514 related articles for article (PubMed ID: 20530976)
1. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
2. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice.
Dutta NK; Mazumdar K; Dastidar SG; Park JH
Int J Antimicrob Agents; 2007 Oct; 30(4):336-40. PubMed ID: 17644321
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
Int J Antimicrob Agents; 2009 Nov; 34(5):451-3. PubMed ID: 19625168
[TBL] [Abstract][Full Text] [Related]
4. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T
J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635
[TBL] [Abstract][Full Text] [Related]
5. Preparation and in-vitro evaluation of 4-benzylsulfanylpyridine-2-carbohydrazides as potential antituberculosis agents.
Herzigová P; Klimesová V; Palát K; Kaustová J; Dahse HM; Möllmann U
Arch Pharm (Weinheim); 2009 Jul; 342(7):394-404. PubMed ID: 19536781
[TBL] [Abstract][Full Text] [Related]
6. [Reasons for drug-resistant tuberculosis emergence].
Tu DH
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):403-5. PubMed ID: 17673006
[No Abstract] [Full Text] [Related]
7. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
[TBL] [Abstract][Full Text] [Related]
8. Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection.
Rodrigues-Junior VS; Dos Santos Junior A; Dos Santos AJ; Schneider CZ; Calixto JB; Sousa EH; de França Lopes LG; Souto AA; Basso LA; Santos DS; Campos MM
Int J Antimicrob Agents; 2012 Aug; 40(2):182-5. PubMed ID: 22748570
[TBL] [Abstract][Full Text] [Related]
9. Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection.
Shoen CM; DeStefano MS; Cynamon MH
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S288-90. PubMed ID: 10875802
[TBL] [Abstract][Full Text] [Related]
10. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
Lenaerts AJ; Gruppo V; Marietta KS; Johnson CM; Driscoll DK; Tompkins NM; Rose JD; Reynolds RC; Orme IM
Antimicrob Agents Chemother; 2005 Jun; 49(6):2294-301. PubMed ID: 15917524
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
12. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
Coban AY; Bilgin K; Uzun M; Durupinar B
Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
[TBL] [Abstract][Full Text] [Related]
13. The potential of azole antifungals against latent/persistent tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 May; 258(2):200-3. PubMed ID: 16640573
[TBL] [Abstract][Full Text] [Related]
14. [A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis].
Lu Y; Wang B; Zhao WJ; Zheng MQ; Li P; Fu L; Liang BW
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Sep; 33(9):675-8. PubMed ID: 21092635
[TBL] [Abstract][Full Text] [Related]
15. Antimycobacterial activity of Citrullus colocynthis (L.) Schrad. against drug sensitive and drug resistant Mycobacterium tuberculosis and MOTT clinical isolates.
Mehta A; Srivastva G; Kachhwaha S; Sharma M; Kothari SL
J Ethnopharmacol; 2013 Aug; 149(1):195-200. PubMed ID: 23816500
[TBL] [Abstract][Full Text] [Related]
16. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs.
Gupta AK; Katoch VM; Chauhan DS; Sharma R; Singh M; Venkatesan K; Sharma VD
Microb Drug Resist; 2010 Mar; 16(1):21-8. PubMed ID: 20001742
[TBL] [Abstract][Full Text] [Related]
17. Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs.
Liang Y; Wu X; Zhang J; Yang Y; Wang L; Bai X; Yu Q; Li N; Li Z
Scand J Immunol; 2011 Jul; 74(1):42-6. PubMed ID: 21352251
[TBL] [Abstract][Full Text] [Related]
18. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis.
Rivas-Santiago B; Rivas Santiago CE; Castañeda-Delgado JE; León-Contreras JC; Hancock RE; Hernandez-Pando R
Int J Antimicrob Agents; 2013 Feb; 41(2):143-8. PubMed ID: 23141114
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the efficiency of activity of the liposomal form of isoniazid against different types of mycobacteria in vitro].
Golyshevskaia VI; Selishcheva AA; Martynova LP; Lepekha LN; Kalashnikova TM; Kornilova ZKh; Erokhin VV; Rozenberg OA
Probl Tuberk Bolezn Legk; 2006; (8):61-4. PubMed ID: 17002062
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base.
Hearn MJ; Cynamon MH
J Antimicrob Chemother; 2004 Feb; 53(2):185-91. PubMed ID: 14688045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
